Brain Metastasis, Melanoma
Conditions
Keywords
melanoma, brain metastasis, stereotactic radiosurgery, Ipilimumab, survival, safety, efficacy
Brief summary
This is a non-controlled, open label, Phase II Study of ipilimumab combined with a Stereotactic Radiosurgery. The study included an induction phase of four IV infusions of Ipilimumab at 10 mg/kg every 3 weeks associated with a stereotactic radiosurgery performed 3 days before 2nd ipilimumab administration. A Maintenance phase included Ipilimumab, IV, 10 mg/kg once every 12 weeks, starting at week 24, in the absence of PD, unacceptable toxicity or withdrawal of consent or disease progression. The primary objective is the overall survival. The Secondary objectives include safety, ORR, PFS and peripheral blood absolute lymphocyte count (ALC) as a predictive biomarker.
Interventions
DRUGIPILIMUMAB
RADIATIONStereotactic radiosurgery
Sponsors
Bristol-Myers Squibb
University Hospital, Lille
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Willing and able to give written informed consent. 2. Men and women ≥ 18 years of age. 3. Patient eligible to single dose Stereotactic Radiotherapy (Radiosurgery) as per the pluridisciplinary committee. 4. Neurologically asymptomatic or pauci-symptomatic patients. Patients with moderated neurological symptoms without systemic corticosteroids treatment can be included. 5. Less than 4 brain metastasis at the MRI. Brain metastasis should measure less than 3 cm in diameter. At least one brain metastasis \> 5mm. 6. Maximum one prior systemic therapy for metastatic disease is allowed. 7. Prior treatment with INTERFERON in the adjuvant setting is authorized. Prior treatment with anti-CTLA-4 is NOT authorized. 8. ECOG Performance Status 0 or 1 9. Within the last 2 weeks prior to study day 1 the following laboratory parameters, which should be within the ranges specified:
Exclusion criteria
1. The patient requires concomitant chronic treatment with systemic corticosteroids or any other immunosuppressive agents 7 days prior to inclusion. 2. Neurological symptoms treated with systemic corticosteroids (whatever the dose of corticoids). 3. The patient has concurrent severe medical problems, unrelated to the malignancy, that would significantly limit full compliance with the study or expose the patient to unacceptable risk such as but not limited to: Cardiac insufficiency (III or IV as per NYHA classification), Renal insufficiency, ongoing infection. 4. Any symptom of concomitant tumour meningitis 5. History of immediate or delayed gadolinium hypersensitivity, or any contraindication to undergo MRI examination (Pacemaker, brain aneurysms clips) 6. Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of the cervix (Subjects with a previous malignancy but without evidence of disease for 5 years will be allowed to enter the study) 7. Uncontrolled infectious diseases - requires negative tests for clinically suspected HIV, HBV and HCV. If positive results are not indicative of true active or chronic infection, the subject may enter the study after discussion and agreement between the Investigator and the Medical Monitor. 8. Active autoimmune disease. Autoimmune disease: subjects with a documented history of inflammatory bowel disease, including ulcerative colitis and Crohn's disease are excluded from this study as are subjects with a history of symptomatic disease (e.g., rheumatoid arthritis, systemic progressive sclerosis \[scleroderma\], Systemic Lupus Erythematosus, autoimmune vasculitis \[e.g., Wegener's Granulomatosis\]). 9. Subjects with motor neuropathy considered of autoimmune origin (e.g., Guillain Barré Syndrome) are excluded from this study 10. Previous treatment with a CTLA-4 antagonist agent, including treatment in adjuvant setting. 11. The patient has psychiatric or addictive disorders that may compromise his/her ability to give informed consent or to comply with the trial procedures. 12. Lack of availability for clinical follow-up assessments. 13. For female patients: the patient is pregnant or lactating. 14. Women of childbearing potential: refusal or inability to use effective means of contraception 15. Participation in another clinical trial protocol within 30 days prior to enrolment 16. Persons protected by a legal regime (guardianship, trusteeship) 17. Patients in emergency situations 18. Patients kept in detention
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival rate | until week 96 or death |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall response rate in brain | until week 96 or death | according to immune-related response criteria (ir-RC) and the mWHO criteria of target lesion |
| Global overall response rate | until week 96 or death | according to immune-related response criteria (ir-RC) and the mWHO criteria of target lesions |
| All adverse events ≥ Grade 3 according to CTCAE, Version 4.0 criteria, | through study completion, until week 96 | — |
| Global disease control rate | until week 96 or death | according to immune-related response criteria (ir-RC) and the mWHO criteria of target lesions |
| Progression free survival | until week 96 or death | — |
| Disease control rate in brain | until week 96 or death | according to immune-related response criteria (ir-RC) and the mWHO criteria of target lesions |
Countries
France
Outcome results
None listed